

Explore the expanding Amneal Biosciences portfolio

We deliver high-quality, essential medicines. To increase choice, access, and affordability, we have expanded our offerings to include **biosimilars and ready-to-use oncology injectables.**¹





Learn about our PATHways[®] patient support program

Look to the Amneal PATHways program's full suite of services to help you deliver the most affordable care possible, for every patient.







Ready-to-use oncology injectables

FDA-approved biosimilars: Increasing access while lowering cost

A biosimilar is a therapeutic product that the FDA has determined to be highly similar to an approved biologic and has no clinical differences in terms of safety and effectiveness.²

ALYMSYS[®] (bevacizumab-maly)

Reference product: Avastin® (bevacizumab)³ Description: Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg⁴

- Diluted solution can be stored for up to 12 hours at 2°C to 8°C (36°F to 46°F)³
- Extended shelf life of up to 30 months in unopened vial⁵

Unit of sale ³	Unit of sale quantity	NDC
100 mg/4 mL	1 vial	70121-1754-1
100 mg/4 mL	10 vials	70121-1754-7
400 mg/16 mL	1 vial	70121-1755-1
400 mg/16 mL	10 vials	70121-1755-7
HCPCS code⁴: Q5126		

FYLNETRA[®] (pegfilgrastim-pbbk)

Reference product: Neulasta® (pegfilgrastim)6

Description: Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg⁴

- Prefilled syringe⁶
- Store refrigerated between 36°F to 46°F (2°C to 8°C) in the carton to protect from light⁶

Unit of sale ⁶	Unit of sale quantity	NDC
6 mg/0.6 mL	1 prefilled syringe	70121-1627-1
HCPCS code⁴: Q5130		

RELEUKO® (filgrastim-ayow)

Reference product: Neupogen® (filgrastim)7

Description: Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram⁴

- Extended shelf life of up to 24 months⁵
- Store refrigerated between 2°C to 8°C (36°F to 46°F)⁷

Unit of sale ⁷	Unit of sale quantity	NDC		
300 mcg/0.5 mL	1 prefilled syringe	70121-1568-1		
300 mcg/0.5 mL	10 prefilled syringes	70121-1568-7		
480 mcg/0.8 mL	1 prefilled syringe	70121-1570-1		
480 mcg/0.8 mL	10 prefilled syringes	70121-1570-7		
HCPCS code⁴: Q5125				

FDA, US Food and Drug Administration; HCPCS, Healthcare Common Procedure Coding System; IV, intravenous; NDC, National Drug Code.

	NOC 20121-170			CHILDER SHOT	to table 10	1222 - Sec. 4			
No man 1750 i Adverses Avacuation of the second bactor of the second of	Alyn (bevaciaur lijettion 400 mg/ For Introvension for Introvension for Introvension for Introvension for Introvension	16 mL (25 us Infusion Dose Vial, of Portion.	5 mg/mL)	pepratie be i (5 egiti) sign	Alymsy bevacizumab-ma lrjection	25 mg/mL)	CREET Sub co provide to to 2 mplot adult 2 m	it op int and eld of 5 mg basectment, 4 glychut,	FERRIT FILTER





FOCINVEZ[™] (fosaprepitant injection)

Description: Injection, fosaprepitant (focinvez), 1 mg⁴

- A ready-to-use IV solution, without the need for dilution or reconstitution⁹
- Administered directly from the vial using included vial hanger⁹
- Shelf stable for up to 90 days at room temperature⁹

Unit of sale ⁹	Unit of sale quantity	ND
150 mg/50 mL	Single-dose vial	701
HCPCS code⁴: J1434		

PEMRYDI RTU® (pemetrexed injection)

Description: Injection, pemetrexed (pemrydi rtu), 10 mg⁴

- No reconstitution or dilution needed¹⁰
- Stable at room temperature in original packaging¹⁰
- Withdraw the calculated dose from the vial(s) and transfer to an empty IV bag¹⁰

Unit of sale ¹⁰	Unit of sale quantity	ND
100 mg/10 mL	Single-dose vial	701
500 mg/50 mL	Single-dose vial	701
HCPCS code⁴: J9324		

BORUZU® (bortezomib injection)

Description: Injection, bortezomib (boruzu), 0.1 mg¹¹

- A ready-to-use presentation of bortezomib for subcutaneous administration¹²
- Does not require reconstitution¹²
- Store BORUZU[®] refrigerated at 2°C to 8°C (36°F to 46°F) in original package to protect from light¹²


Unit of sale ¹²	Unit of sale quantity	ND
3.5 mg/1.4 mL	Single-dose vial	701
HCPCS code ¹¹ : J9054		





Ready-to-use oncology injectables: Supporting operational efficiency


The 505(b)(2) FDA regulatory approval pathway allows for enhancements in product characteristics that may support operational efficiency, such as simplified storage and preparation.⁸





121-2453-1 121-2461-1







Scan QR code for more information







Fylnetra (pegfilgrastim-pbbk)

















References: 1. Amneal Pharmaceuticals. 2023 Amneal environmental, social and governance report. June 2024. Accessed Nov. 23, 2024. https://amneal.com/wpcontent/uploads/2023/06/Amneal-ESG-report-2022.pdf 2. Amneal Pharmaceuticals. 2022 Amneal environmental, social and governance report. June 2023. Accessed November 23, 2024. https://amneal.com/wp-content/uploads/2023/06/Amneal-ESG-report-2022.pdf 3. ALYMSYS. Prescribing information. Amneal Pharmaceuticals LLC; 2022. 4. Centers for Medicare & Medicaid Services. First quarter, 2025 HCPCS quarterly update. December 17, 2024. Accessed January 14, 2025. https://www.cms.gov/medicare/ coding-billing/healthcare-common-procedure-system/quarterly-update 5. Data on file. Amneal Pharmaceuticals. 6. FYLNETRA. Prescribing information. Amneal Pharmaceuticals LLC; 2022. 7. RELEUKO. Prescribing information. Amneal Pharmaceuticals LLC; 2022. 8. US Food and Drug Administration. Overview of the 505(b) (2) regulatory pathway for new drug applications. Accessed November 23, 2024. https://www.fda.gov/media/156350/download 9. FOCINVEZ. Prescribing information. Amneal Pharmaceuticals LLC; 2023. 10. PEMRYDI RTU. Prescribing information. Amneal Pharmaceuticals LLC; 2024. 11. Centers for Medicare & Medicaid Services. Fourth quarter, 2024 HCPCS coding cycle. Accessed January 14, 2025. https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-4-2024-drugs-andbiologicals.pdf 12. BORUZU. Prescribing information. Amneal Pharmaceuticals LLC; 2024.

amnealbiosciences.com | amneal.com

BORUZU® is approved by the US Food and Drug Administration but is not yet available for distribution.

ALYMSYS® is a registered trademark of mAbxience Research, S.L.

BORUZU® and PEMRYDI RTU® are registered trademarks of Amneal Pharmaceuticals LLC.

FOCINVEZ™ is a pending trademark of Amneal Pharmaceuticals LLC.

RELEUKO® and FYLNETRA® are registered trademarks of Kashiv BioSciences, LLC.

Amneal Biosciences is a division within Amneal's Generics segment, which is a part of Amneal Pharmaceuticals LLC.

©2025 Amneal Pharmaceuticals LLC. All rights reserved. PP-ADP-BIOSC-US-0012 01/25

